Prevention and early detection clinical trials: opportunities for primary care providers and their patients.
Enrollment into cancer prevention and early detection clinical trials represents a unique challenge compared with a diagnostic or treatment trial because it involves subjects without a diagnosis of cancer. This paper examines some of the barriers to participation in prevention and early detection trials and provides detailed information about two ongoing prevention and two ongoing early detection clinical trials open to enrollment as well as brief summaries of seven additional trials now open to enrollment.
Ford
Leslie G
LG
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Minasian
Lori M
LM
McCaskill-Stevens
Worta
W
Pisano
Etta D
ED
Sullivan
Dan
D
Smith
Robert A
RA
D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis / Q000517:prevention & control; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis*; D008297:Male; D009369:Neoplasms / Q000175:diagnosis* / Q000517:prevention & control*; D018579:Patient Selection; D011320:Primary Health Care; D011471:Prostatic Neoplasms / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use; D012643:Selenium / Q000627:therapeutic use; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D016588:Anticarcinogenic Agents; D000975:Antioxidants; D013629:Tamoxifen; D014810:Vitamin E; D020849:Raloxifene Hydrochloride; D012643:Selenium